A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
- Status
- TERMINATED
- Phase
- PHASE4
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
- Status
- COMPLETED
- Phase
- PHASE4
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
- Status
- TERMINATED
- Phase
- PHASE2
TREatment of degeNerative and Neoplastic Diseases With Rituximab
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior Anti-TNF Therapy (RESET)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
- Status
- TERMINATED
- Phase
- PHASE4
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
- Status
- TERMINATED
- Phase
- PHASE2
Addition of Rituximab to Leflunomide in Patients With Active Rheumatoid Arthritis
- Status
- COMPLETED
- Phase
- PHASE3
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE3
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- NA
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)
- Status
- COMPLETED
- Phase
- PHASE2